13F Pro Quality Score

22.7/100

Rank #2,632 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

16.5/100

Profitability

15.8/100

Balance Sheet

13.9/100

Earnings Quality

30.0/100

Free Cash Flow

30.8/100

Institutional Flow

21.1/100

Revenue Scale

33.3/100

Dilution Risk

39.5/100

ARAY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ACCURAY INC (ARAY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARAY at 22.7/100 on a 32-signal composite quality model, placing it at rank #2,632 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (13.9) and profitability (15.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), ACCURAY INC reports quarterly revenue of $104.8M, net income of $-11.8M, an operating margin of -8.7%. Top institutional holders of ARAY by reported 13-F value include Chicago Capital Management,, ABSOLUTE INVESTMENT ADVISERS,, CAPSTONE INVESTMENT ADVISORS,, based on the most recent SEC filings. ARAY trades on the Nasdaq exchange and files with the SEC under CIK 1138723. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARAY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACCURAY INC directly from SEC EDGAR. ACCURAY INC's 13F Pro composite quality score has ranged between 8 and 44 since 2021, currently 22.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Fun facts about ACCURAY INC

Quirks, history, and lore behind ARAY — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Sunnyvale, California.
  • 2
    The Numbers
    Annual revenue in the range of roughly $200 million — not a giant, but it operates in over 30 countries and its machines carry price tags that make hospitals sweat.
  • 3
    The History
    Founded in the early 2000s and spun out of technology developed at Stanford University, it brought a fresh approach to an existing but clunky field of cancer treatment.
  • 4
    The Secret
    Its flagship system delivers radiation therapy by tracking a tumor in real time and moving with it — so the beam follows the cancer, not a rigid plan made days earlier.
  • 5
    The Lore
    Its CyberKnife system is essentially a robotic radiosurgery platform that can zap tumors anywhere in the body with sub-millimeter precision — no scalpel required.
  • 6
    The Giveaway
    Two flagship products: the CyberKnife robotic radiosurgery system and the TomoTherapy platform — tools that make radiation oncologists feel like they're living in the future.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$104.8M

Net Income

Q3 2026

$-11.8M

Free Cash Flow

Q3 2026

$-6.1M

Operating Margin

Q3 2026

-8.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.1% YoY
$447.6MFY 2023
FY20 $382.9MFY21 $396.3MFY22 $429.9MFY23 $447.6M

Net Income

-73.6% YoY
$-9.3MFY 2023
FY20 $3.8MFY21 $-6.3MFY22 $-5.3MFY23 $-9.3M

Operating Income

-70.8% YoY
$2.4MFY 2023
FY20 $12.5MFY21 $22.2MFY22 $8.1MFY23 $2.4M

EPS (Diluted)

-66.7% YoY
$-0.10FY 2023
FY20 $0.04FY21 $-0.07FY22 $-0.06FY23 $-0.10

Total Assets

+1.3% YoY
$479.2MFY 2023
FY20 $490.9MFY21 $480.1MFY22 $472.8MFY23 $479.2M

Total Debt

-4.5% YoY
$188.7MFY 2023
FY20 $189.3MFY21 $181.4MFY22 $197.6MFY23 $188.7M

Op. Cash Flow

+747.5% YoY
$15.5MFY 2023
FY20 $-1.5MFY21 $38.5MFY22 $-2.4MFY23 $15.5M

AI Insight: ARAY Financial Trends

Revenue stalled at $105M in Q1 2026 — back to Q3 2024 levels — while operating losses deepened and equity eroded to a multi-period low of $42M.

Revenue declined from a $128M peak in Q2 2025 to $105M in Q1 2026, reversing prior growth momentum.

Operating income swung from $4M in Q2 2025 to -$11M and -$12M in Q3–Q4 2025, with -$9M in Q1 2026.

Total debt declined from $191M in Q4 2024 to $147M in Q4 2025, a meaningful $44M reduction over four quarters.

Equity contracted sharply from $81M in Q2 2025 to $42M in Q1 2026, reflecting sustained net losses.

Operating cash flow was negative in three of the last four quarters; persistent outflows threaten the deleveraging trend.

Total debt ticked up to $156M in Q1 2026 from $147M in Q4 2025 — first sequential increase in five quarters.

Equity at $42M against $156M debt signals thin solvency cushion; further losses could pressure covenant compliance.

AI Insight: ARAY Ratio Trends

ACCURAY's profitability collapsed after a Q4 2024 anomaly, with ROIC running at -18.4% and operating margin at -8.7% in Q1 2026.

Operating margin swung from +11.2% in Q4 2024 to -12.0% in Q3 2025 and remains deeply negative at -8.7% in Q1 2026.

ROIC deteriorated sharply from +23.3% in Q4 2024 to -18.4% in Q1 2026, wiping out the prior quarter's gains.

D/E ratio improved from 4.11 in Q3 2024 to 2.00 in Q2 2025 but has since crept back up to 3.75 in Q1 2026.

ROE plunged to -113.2% in Q1 2026, reflecting sustained net losses amplified by an eroded equity base.

Q4 2024's +16.4% NPM and +169.2% ROE appear one-off; underlying profitability has never sustainably recovered.

D/E rebounding to 3.75 in Q1 2026 after touching 2.00 in Q2 2025 — rising leverage alongside losses is a key risk.

Modest sequential improvement in operating margin from -12.0% to -8.7% over two quarters warrants monitoring for a genuine recovery.

Get alerted when ARAY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ACCURAY INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put ARAY on your watchlist

Track score changes the day ACCURAY INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ARAY a good stock to buy?

13F Pro's AI-powered analysis of ACCURAY INC (ARAY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARAY are available on the ARAY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARAY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARAY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACCURAY INC's investment landscape.